All FDA articles – Page 5
-
News
FDA reverses debarment of one of its ex-chemists
US Food and Drug Administration lifts ban on chemist who worked at the agency, more than 20 years after he was sentenced for taking bribes
-
Business
US import ban imposed on Indian pharma firm
Concerns over manufacturing processes at Emcure facility prompts Food and Drug Administration to block drug shipments
-
FeaturePharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits
-
News
NIH plan to get drug development unit back online
The US National Institutes of Health to address deficiencies in unit that makes drugs for research studies
-
News
NIH drug manufacturing unit shut down
The US National Institutes of Health suspends operations at its pharmaceutical development section after FDA inspectors uncover serious manufacturing issues
-
News
California demands warning labels for BPA
Despite safety evidence, the state has added BPA to its list of cancer-linked chemicals under ‘Proposition 65’
-
Business
Injunction blocks first US biosimilar
Despite regulatory approval, Amgen is delaying sales of Sandoz’s version of filgrastim
-
Business
FDA accused of violating drug company’s freedom of speech
Amarin says the regulator is stopping it from giving ‘truthful, not misleading’ information to doctors about its fatty acid drug
-
Business
Drug firms warned to be honest with investors
Official warns of ‘significant consequences’ if companies aren’t forthcoming about their FDA interactions
-
Business
US approves biosimilar filgrastim
Sandoz’s version of Amgen’s Neupogen is ‘biosimilar’ but not ‘interchangeable’
-
NewsCaramel colour in soft drinks linked to cancer
Regulatory bodies and researchers sceptical of study on 4-MEI found in food colour
-
BusinessUS opens up home DNA screening
FDA approves single disease genetic test and clears pathway for similar devices
-
Business
Teva wins generic esomeprazole race
US approval of heartburn drug after Ranbaxy version was withdrawn by regulators
-
Business
EU regulator calls for generic drug suspensions
The EMA wants hundreds of formulations off the market after identifying systematic fraud in a major Indian contract clinical research organisation
-
BusinessUS poised to approve its first ‘biosimilar’ drug
FDA panel recommends Sandoz’s copy of Amgen’s Neupogen
-
-
Business
Ranbaxy sues over withdrawn US approvals
Company says decision is ‘unconstitutional’ and deprives it of hundreds of millions of dollars in revenue
-
Business
Single shot antibiotic approved for skin infections
Third drug in three months approved under US antimicrobials incentive scheme
-
Business
Drug giants settle mismarketing lawsuits
Pfizer and GSK settle claims over promoting drugs for unapproved uses in the US